Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway by De Velasco, Marco A. & Uemura, Hirotsugu
Hindawi Publishing Corporation
Advances in Urology
Volume 2012, Article ID 419348, 12 pages
doi:10.1155/2012/419348
Review Article
PreclinicalRemodelingof Human Prostate Cancerthrough
thePTEN/AKT Pathway
Marco A. De Velasco1,2 andHirotsuguUemura1
1Department of Urology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan
2Department of Genome Biology, Kinki University School of Medicine, Osaka-Sayama, Osaka 589-8511, Japan
Correspondence should be addressed to Hirotsugu Uemura, huemura@med.kindai.ac.jp
Received 1 November 2011; Accepted 4 December 2011
Academic Editor: Jack Schalken
Copyright © 2012 M. A. De Velasco and H. Uemura. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Knowledge gained from the identiﬁcation of genetic and epigenetic alterations that contribute to the progression of prostate
cancer in humans is now being implemented in the development of functionally relevant translational models. GEM (genetically
modiﬁed mouse) models are being developed to incorporate the same molecular defects associated with human prostate cancer.
Haploinsuﬃciency is common in prostate cancer and homozygous loss of PTEN is strongly correlated with advanced disease.
In this paper, we discuss the evolution of the PTEN knockout mouse and the cooperation between PTEN and other genetic
alterations in tumor development and progression. Additionally, we will outline key points that make these models key players
in the development of personalized medicine, as potential tools for target and biomarker development and validation as well as
models for drug discovery.
1.Introduction
A major breakthrough in the developmental strategy for
the treatment of prostate cancer came through in 1941
when Huggins discovered that metastatic prostate cancer
responds to androgen ablation thus ushering in a new era
in the treatment of prostate cancer therapy [1]. Androgen
deprivation therapy remains the most powerful treatment
for advance prostate cancer and newer generation androgen
deprivation therapies (ADTs) that more eﬀectively inhibit
AR signaling are rapidly being developed and approved
for patients with metastatic CRPC. However, therapeutic
eﬀects are short lived and eventually all patients succumb
to the disease [2]. The prognosis for men with CRPC is
bleakascurrentlyavailableapprovedtreatmentsonlyprovide
marginal beneﬁt and systemic treatments for metastatic
CRPC are primarily approved for the management of
symptoms [3, 4]. Recently, cytotoxic treatments such as the
combinations of prednisone plus docetaxel or cabazitaxel
demonstrated modest improvements in extended survival
b u th a v ey e tt op r o d u c el o n g - t e r mb e n e ﬁ t s[ 5–7].
A better understanding of the biology of prostate cancer
has resulted in the identiﬁcation of novel therapeutic targets
andthusencouragedthedevelopmentofnewsmallmolecule
therapeutic agents that target quintessential factors that are
now known to contribute to tumor growth, development
and progression. A large number of novel therapeutics are
currently undergoing clinical evaluation for the treatment
of prostate cancer, and small molecule signal transduction
inhibitors are a promising class of agents. These inhibitors
have recently become standard therapy and have been FDA
approvedforthetreatmentofvarioussolidcancersincluding
renal, GIST, breast, pancreas, colon, and NSCLC and oﬀer
signiﬁcant promise in prostate cancer [8–14].
The development of an eﬀective treatment strategy to
treat advanced prostate cancer has been challenging due in
fact to the heterogeneity of the disease. Complex genomic
aberrations targeting multiple genes through mutation,
changes in copy number, and methylation make patient se-
lection diﬃcult for the use of targeted molecular inhibitors
[15]. The ﬁrst steps have already been taken to identify
some of the genetic alterations that lead to perturbed cell
signaling pathways that contribute to tumor development
and progression. However, developing eﬀective therapeutic
strategies will require relevant preclinical models of prostate
cancer to identify and validate therapeutic targets and bio-
markers.2 Advances in Urology
2. PreclinicalModeling for ProstateCancer
Traditional medical intervention treatments for prostate
cancer are based on data from epidemiological, clinical, or
evidence-based medicine. However, this model is optimized
for a large population and not for any one particular individ-
ual. The recent trend in medicine is to employ a personalized
treatment approach that is based on molecular proﬁling
to determine the best treatment strategy for a particular
individual. This approach requires the development of new
high-throughput technologies to decipher and interrogate
tumors at various molecular levels and integrates resources
from various specialized ﬁelds into one system to discover,
coordinate, and extract a strategic approach derived from
multidimensional input data.
Cancer is a complex heterogeneous disease that involves
genetic events that lead to the disruption of multiple
signalingnetworks.Consequently,multiplecellularprocesses
within the tumor microenvironment within a host system
are involved and may be inﬂuenced by any number of envi-
ronmental factors over a period of time. Basically, the “one
gene, one protein, one function” hypothesis is outdated and
not applicable for systems biology. Until recently, preclinical
models for prostate cancer have been limited largely due to
the lack of animal models that develop spontaneous prostate
tumors in a manner similar to humans. Spontaneous animal
models such as dog and rat have been used extensively to
study hormonal carcinogenesis but are impractical and do
not represent a feasible model for preclinical eﬃcacy evalua-
tion [16, 17]. Mouse xenograft models derived from human
prostatetumorcellhavebeendevelopedandusedextensively
in academia and pharmaceutical industry. Although the
number of human prostate cancer cell lines is limited, the
convenience and low cost have made the xenograft model
popular for gene validation and compound testing [18, 19].
During a 10-year period (1991–2000) big pharma com-
panies in the United States and Europe reported that only
5 out of 100 drugs passing preclinical testing achieved
drug approval success [20]. The majority of attrition (70%)
occurred in Phase II trials with lack-of-eﬃcacy accounting
for approximately 30% of failures. Lack of treatment eﬃcacy
in Phase II and III trials has been attributed to unpredictable
preclinical models [20, 21]. Pharmaceutical companies rou-
tinely use human prostate cancer cell xenografts during
the preclinical testing phase to evaluate new drug eﬃcacy.
However, only three human prostate cancer cells lines (PC3,
DU145, and LNCaP) account for vast majority of cells used
in prostate cancer drug eﬃcacy screens. The use of these
cells to study human prostate cancer in vivo is inadequate as
they lack many key features found in autochthonous cancers.
While xenograft models (ectopic or orthotopic) may have
value in certain situations, they are inappropriate and bear
little relevance to human prostate cancer.
With the development of GEM (genetically engineered
mice), preclinical modeling for prostate cancer has evolved
signiﬁcantly in the last 15 years [16–23]. These models
consistofmicethathavebeendesignedtodeliberatelyinhibit
or express a particular gene function through the intro-
duction of foreign DNA. Today, GEM have become quite
sophisticated and allow for any combination of tissue-
speciﬁc expression of oncogenes as well as conditional,
tissue-speciﬁc deletion of tumor suppressors. The value of
GEM modeling relies on the development of transgenic mice
that possess most of the clinicopathological and molecular
characteristics of human prostate cancer.
3.Biology of ProstateCancerandPTEN
Prostate cancer progression follows a series of deﬁned states
characterized by molecular changes associated with disease
progression. The heterogeneity of prostate cancer has pre-
vented clear identiﬁcation and correlation of critical genetic
events contributing to disease progression and treatment
resistance. However, there are constant genetic alterations
frequently present in prostate cancer such as the loss of
PTEN function. PTEN, located on chromosome 10 (10q23),
is a tumor suppressor gene that is broadly expressed during
development and adulthood and is essential for embryogen-
esis[24].PTEN encodesaduallipidandproteinphosphatase
that functions as an inhibitor of PIP3 [25]. Accumulation of
PIP3 then mimics the eﬀect of phosphatidylinositol 3-kinase
(PI3K) activation resulting in the activation of downstream
eﬀectors including Akt. Activation of Akt phosphorylates
various physiological substrates that results in the stim-
ulation of cell cycle progression, survival, migration, and
metabolism [24–27].
PTEN function lost through mutations, deletions, or
promotermethylationsilencingoccursatahighfrequencyin
many primary and metastatic human cancers in humans and
is the second most commonly tumor suppressor gene after
p53 [24, 26–28]. Current estimates suggest that PI3K/Akt/
mTOR signaling is upregulated in 30–50% of prostate
cancers, often through loss of PTEN function [29, 30].
Clinical ﬁndings have demonstrated that biallelic deletion
of PTEN correlates with disease-speciﬁc mortality and is
associated with Akt and AR deregulation [30–32]. Published
reports have shown that heterozygous loss of PTEN occurs
in as many as 70–80% of primary tumors, and complete
inactivation occurs in 20% of primary tumors and 63% of
metastasis [29, 33, 34]. A more recent report showed that
copy-number alterations (CNAs) in prostate cancer were
present in 42% of primary tumors and 100% of metastases
[35].
It has been widely recognized that AR signaling remains
important even in the presence of reduced androgen levels
and thus remains a major target for targeted therapeutic
interventions [36]. Clinically, the deletion of PTEN and
AR expression has been signiﬁcantly correlated to cancer-
speciﬁc mortality in patients with CRPC [31]. Reports
suggest that PI3K through AKT may play an important role
in upregulating AR protein expression in the absence of
PTEN [37, 38]. PTEN can modulate AR activity directly
or through PI3K/Akt signaling pathways; however, levels
of AR are often heterogeneous in late-stage disease [39–
41]. Evidence from published reports has now shown that
alterations in AR develop with sequential hormonal ablation
therapies and tumor progression [42, 43]. Also, reciprocal
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cancerinitiates a series of molecular events that contribute to
growth survival and diﬀerentiation and may thus participate
in ADT resistance. It was recently demonstrated that loss
of AR expression, in the absence of PTEN, can lead to
downregulation of Fkbp5 and PHLPP-mediated Akt inhi-
bition resulting in increased cellular proliferation [44, 45].
Therefore, it is essential to develop and test new compounds
that target known compensatory and survival pathways in
advanced prostate cancer and identify new targets for po-
ssible interventions.
4. TraditionalPTENKnockoutMouseModelsof
ProstateCancer
The strong implication of PTEN in prostate cancer pro-
gression in humans has prompted the development of
genetically GEM models based on PTEN inactivation (see
Table 1). Traditional knockout models of PTEN developed
in the late 1990’s were generated by deleting exons 4, or
4a n d5o ft h ePTEN gene, which codes for the entire
PTEN-phosphatase domain and part of the two α-helix
motifs ﬂanking the catalytic core [46, 47]. Homozygous
inactivation of PTEN results in normal appearing, but
nonviable embryos. Heterozygous PTEN knockout mice are
born viable to develop prostatic intraepithelial neoplasia
(PIN) in the prostate as well as a neoplasias in a number
of organs including skin, colon, endometrium, liver, thyroid,
and thymus [46, 47]. However, progression to malignant
adenocarcinoma is not observed in heterozygous mutants
indicating that inactivation of one allele of PTEN is enough
to initiate tumorigenesis but not progression. It is important
to note that the viability of the mice is compromised by
lymphoid proliferation and development of tumors arising
in other organs such as intestines, mammary, thyroid,
endometrial, and adrenal glands.
Increased phosphorylation of Akt occurs as a result of
PTEN inactivation;however,itwasuncertainwhetherhyper-
activation of Akt was enough to drive tumor development
in the prostate. To address this question, one group looked
at the eﬀects of Akt overexpression in the mouse prostate
using the MPAKT transgenic mouse [57]. Overexpression of
Akt1 in MPAKT transgenic mice results in the development
of PIN in the ventral prostate but not cancer. Thus activation
of Akt signaling alone in the presence of PTEN is insuﬃcient
to induce prostate cancer although the deletion of Akt1
but not Akt2 (Akt1 is the predominant isoform found in
mouse prostate) was suﬃcient to suppress the development
of high-grade PIN lesions in PTEN+/− mice [54, 58]. These
ﬁndings not only cement the role of PTEN in early prostate
carcinogenesis but also demonstrate the multifunctional role
of PTEN in regulating other biological processes related
to malignant transformation. Prostate cancer in humans
displays a range of clinical phenotypes that develops over
time as a result of gene alterations involving multiple
regulatory pathways [59, 60]. In order to achieve clinically
relevant models of human prostate cancer in mice, several
investigators have sought to generate bigenic knockout mice
that combine PTEN haploinsuﬃciency with other genetic
alterations to further characterize the role of PTEN in
prostate tumorigenesis.
Alterations of p53 and retinoblastoma (Rb)o n c o g e n e s
correspond to prostate cancer progression in humans [61,
62]. One particular study used the TRAMP mouse model
to investigate the cooperation between PTEN haploinsuf-
ﬁciency and abrogated function of the tumor suppressor
genes p53 and Rb in prostate cancer development [49].
The TRAMP mouse model is a ﬁrst generation transgenic
knockout and was one of the ﬁrst mouse models to eﬀec-
tively induce the development of aggressive prostate tumors
through the expression of large/small SV40 tumor antigens
(T/tag)underthecontroloftheprostate-speciﬁcratprobasin
promoter [22]. The transforming activity of T/tag inactivates
both p53 and Rb tumor suppressor proteins [63]. Prostate
cancer progression in PTEN+/−/TRAMP mutant mice shows
increasedratesoftumordevelopmentanddecreasedsurvival
compared to PTEN+/+/TRAMP mice. A diﬀerent study
used the Ink4a/Arf−/−PTEN+/− model to investigate the
cooperation between PTEN haploinsuﬃciency and RB and
p53 [50]. The Ink4a/Arf gene focus regulates the tumor
suppressorproteinsRBandp53throughp16Ink4a andp19Ar f,
respectively [64]. Ink4a/Arf−/−PTEN+/− mice experienced a
much faster rate of PIN development compared to Ink4a/
Arf+/+PTEN+/− controls;however,thesemicedidnotdevelop
adenocarcinomas [50].
Deletions of chromosome 12p11-13 (corresponding to
CDKN1B(p27/Kip1I0)) have been identiﬁed in advanced
human prostate cancer suggesting a tumor suppressor role
for p27(Kip1) [48]. Loss of p27(Kip1) function has been
implicated with prostate tumor recurrence and poor disease-
free survival in humans [65, 66]. p27−/− mice develop
enlarged hyperplastic prostates and increased ﬁbromuscular
stromal cells closely resembling benign prostatic hyperplasia
(BPH) but fail to develop prostate cancer [67]. However,
when these mice are bred with heterozygous PTEN mutant
mice, all resulting p27−/−/Pten+/− mutant mice became
susceptible to the development of invasive prostate adeno-
carcinomas[68].Theseanimalmodelshaveprovidedgenetic
evidence to show that collaboration between PTEN haploin-
suﬃciency and inactivation of other tumor suppressor genes
by either gain or loss of function promotes prostate cancer
progression.
Nkx3.1 is a transcription factor whose expression is
androgen dependent and limited to the luminal cell com-
partmentsinprostateglandulartissue[69].AlthoughNkx3.1
mutationsarenotreportedinhumans,lossofNkx3.1protein
expression is strongly correlated to CRPC and advanced
stage prostate cancer [70, 71]. The cooperative function
of PTEN and Nkx3.1 haploinsuﬃciency was explored in a
double knockout transgenic mouse model [51–53]. In this
model, double heterozygous mutants demonstrate a propen-
sity to develop invasive prostate adenocarcinoma after 12
months of age and frequently display iliac lymph node
metastases. In contrast, Nkx3.1 knockout mice only develop
PIN lesions [72, 73]. Another interesting observation with
Nkx3.1+/−/PTEN+/− mice is the ability for these mice to de-
velop CRPC after castration.4 Advances in Urology
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The ERG gene is frequently translocated to the TMPRSS2
promoter region; the resulting TMPRSS2-ERG fusion pro-
tein is positively expressed in half of human prostate
cancer cases [74–76]. Mice expressing the truncated ERG
product from TMPRSS2-ERGa, under the control of the
androgen-responsive region (ARR2Pb) probasin promoter
(functionally analogous to the TMPRSS2-ERGa fusion prod-
uct), only develop PIN [75]. In the presence of PTEN
haploinsuﬃciency,overexpressionofARR2Pb-ERGresultsin
the progression of PIN lesions to prostatic adenocarcinoma
[55]. This model has conﬁrmed that two common critical
events, concomitant loss of PTEN and EGR genetic rear-
rangement, accelerate initiation and progression in human
prostate adenocarcinoma. Stat3 has been implicated in
the promotion and progression of human prostate cancer
[77]. Transgenic mice designed to constitutively express
Stat3 under the control of ARR2Pb develop PIN but fail
to progress to malignant adenocarcinoma; however, when
crossed with PTEN+/− mutant mice, the resultant double
knockouts develop invasive adenocarcinomas [56]. Phos-
phorylated Stat3 expression was potentiated by the loss of
PTEN and subsequent overexpression of Akt. Collectively,
these studies have shown the crucial relevance of “two
hits” for the development of prostate adenocarcinoma and
demonstrated how genetic alterations that play subtle roles
in tumor initiation cooperate with PTEN haploinsuﬃciency
to produce malignant phenotypes in mice similar to human
prostate adenocarcinoma.
5. Conditional PTEN Knockout Mouse Models
of Prostate Cancer
Development of conditional gene targeting by the Cre-LoxP
system has signiﬁcantly changed the landscape for transgenic
mouse modeling research. In conditional mouse models,
the target gene is ﬂanked by LoxP cassettes and remains
in the germline. Inactivation of this gene is controlled by
Cre recombinase which catalyzes recombination between
the two LoxP sites [78]. Orientation of the LoxP cassettes
determines type of recombination to produce deletion,
inversions, or chromosomal translocations [79]. Expression
of Cre is dependent on transgene expression of a widespread
or tissue-speciﬁc promoter. A variation of this system uses
an inducible transgene promoter that is inactive until it is
induced by an activating agent [80]. Conditional knockout
models have the ability to induce the genetic mutation
in the target tissue without aﬀecting nontargeted cells. In
this manner, both genes can be knocked out in the target
cells while the rest of the mouse cells retain normal gene
expression and function.
Promoter selection is critical for targeting the prostate
gland,andseveralhavebeencharacterizedandwelldescribed
in the literature [16, 81–83]. The most common promoters
usedinprostate-speciﬁcconditionaltargetingaretheprostate
speciﬁc antigen-Cre (PSA−Cre), probasin-Cre (PB−Cre), and
ARR2PB-Cre(PB−Cre4)pr omoters[84–88].Themousemam-
mary tumor virus (MMTV−Cre) promoter has also been used
to conditional drive mutations in the prostate; however,
its activity was not speciﬁc to the prostate gland [89].
Inducible promoters used for conditional targeting of the
mouse prostate include PSACreERT2 and Nkx3.1CreERT2,b o t h
inducible with tamoxifen [90, 91]. Floxed PTEN mice have
been developed by ﬂanking exons 4, or 4 and 5 with LoxP
cassettes [84, 92–94]. As in traditional knockouts, these
sites correspond to the coding regions for the entire PTEN-
phosphatase domain and portion of the two α-helix motifs
ﬂanking the catalytic core [46, 47].
We and others have generated prostate-speciﬁc condi-
tional mouse models of prostate cancer to better characterize
full loss of PTEN gene expression and its eﬀect on prostate
tumor carcinogenesis, summarized in Table 2.H e t e r o z y g o u s
PTENloxp/+ mice develop PIN in a manner similar to tradi-
tional heterozygous PTEN knockouts [84–86, 89]. However,
PTEN inactivation under the control of PSACre or PBCre4
promoter in PTENloxp/+ mice is largely restricted to the
prostate, and trace levels of PTEN deletion are seen in the
seminal vesicles [84–86]. Complete inactivation of PTEN
in traditional knockouts results in embryonic lethality thus
limiting the characterization of total PTEN inactivation.
Development of PIN occurs quickly in homozygous PTEN
knockout mice ranging from 6 to 16 weeks of age, and
latency to the development of prostate adenocarcinoma
varies from 9 to 24 weeks [84–86, 89]. Locally invasive
disease is present in these models and some mice develop
metastases to iliac lymph nodes, and occasionally lung [84–
86]. A clinically relevant feature of prostate-speciﬁc PTEN
conditional knockout mice is the sensitivity to androgen
ablation and the ability to develop CRPC [85, 91].
Altogether, these studies have shown that prostate-
speciﬁc conditional PTEN knockout mice share many fea-
tures seen in human prostate cancer. Biallelic inactivation
of PTEN leads to hyperproliferation that is followed by the
development of PIN which eventually progresses to locally
invasiveadenocarcinomaandeventualmetastases.Moreover,
tumors are initially responsive to androgen ablation and
develop into CRPC. Besides histopathological similarities,
tumors from these mice also share molecular proﬁles similar
to human prostate cancer [96]. Inducible variations of
the prostate-speciﬁc conditional knockout model provide
spatiotemporal control of induced mutagenesis [90, 91]. The
ability to incorporate bigenic gene alterations to mice with
conditional PTEN haploinsuﬃciency makes it a relevant
preclinical model to study the epigenetic events or LOH that
lead to disease progression.
6. PTEN Knockout Mice as
DrugTargeting Models
GEM models oﬀer several unique advantages over the xeno-
graft model. The ﬁrst and probably most important feature
is that through controlled gene disruption, these mice can be
manipulated to develop prostate cancer from phenotypically
normal cells, thus encompassing the whole spectrum of
tumor carcinogenesis. Secondly, tumors develop in situ
taking into account all the components involved in the
carcinogenesis process, including interactions with all tumor
microenvironment factors that can promote tumor develop-
ment. Another key feature of these mice is that they retain6 Advances in Urology
T
a
b
l
e
2
:
C
o
n
d
i
t
i
o
n
a
l
P
t
e
n
k
n
o
c
k
o
u
t
m
o
u
s
e
m
o
d
e
l
s
o
f
p
r
o
s
t
a
t
e
c
a
n
c
e
r
.
D
e
s
c
r
i
p
t
i
o
n
P
T
E
N
g
e
n
e
t
i
c
m
a
n
i
p
u
l
a
t
i
o
n
G
e
n
e
k
n
o
c
k
o
u
t
l
e
v
e
l
P
t
e
n
m
u
t
a
t
i
o
n
l
o
c
u
s
M
o
u
s
e
s
t
r
a
i
n
P
h
e
n
o
t
y
p
e
C
a
s
t
r
a
t
i
o
n
r
e
s
i
s
t
a
n
c
e
C
o
m
m
e
n
t
s
Y
e
a
r
R
e
f
.
P
B
C
r
e
4
/
P
t
e
n
l
o
x
p
/
l
o
x
p
C
o
n
d
i
t
i
o
n
a
l
S
i
n
g
l
e
E
x
o
n
s
4
a
n
d
5
1
2
9
S
v
J
y
/
C
5
7
B
L
/
6
H
o
m
o
z
y
g
o
u
s
d
e
l
e
t
i
o
n
r
e
s
u
l
t
s
i
n
i
n
v
a
s
i
v
e
a
d
e
n
o
c
a
r
c
i
n
o
m
a
a
n
d
m
e
t
a
s
t
a
t
i
c
s
p
r
e
a
d
t
o
l
y
m
p
h
n
o
d
e
s
N
o
t
r
e
p
o
r
t
e
d
A
R
R
2
P
B
-
C
r
e
p
r
o
m
o
t
e
r
-
d
r
i
v
e
n
;
1
0
0
%
o
f
m
i
c
e
d
e
v
e
l
o
p
e
d
i
n
v
a
s
i
v
e
c
a
r
c
i
n
o
m
a
a
t
6
m
o
n
t
h
s
2
0
0
3
[
8
4
]
P
B
C
r
e
4
/
P
t
e
n
l
o
x
p
/
l
o
x
p
C
o
n
d
i
t
i
o
n
a
l
S
i
n
g
l
e
E
x
o
n
5
C
5
7
B
L
/
6
/
D
B
A
2
/
1
2
9
/
B
A
L
B
/
c
H
o
m
o
z
y
g
o
u
s
d
e
l
e
t
i
o
n
r
e
s
u
l
t
s
i
n
i
n
v
a
s
i
v
e
a
d
e
n
o
c
a
r
c
i
n
o
m
a
a
n
d
m
e
t
a
s
t
a
t
i
c
s
p
r
e
a
d
t
o
l
y
m
p
h
n
o
d
e
s
Y
e
s
A
R
R
2
P
B
-
C
r
e
p
r
o
m
o
t
e
r
-
d
r
i
v
e
n
;
P
i
n
l
e
s
i
o
n
s
d
e
v
e
l
o
p
a
t
6
w
e
e
k
s
a
n
d
i
n
v
a
s
i
v
e
a
d
e
n
o
c
a
r
c
i
m
o
a
b
y
9
w
e
e
k
s
2
0
0
3
[
8
5
]
M
M
T
V
C
r
e
/
P
T
E
N
l
o
x
p
/
l
o
x
p
C
o
n
d
i
t
i
o
n
a
l
S
i
n
g
l
e
E
x
o
n
s
4
a
n
d
5
C
5
7
B
L
/
6
H
o
m
o
z
y
g
o
u
s
d
e
l
e
t
i
o
n
r
e
s
u
l
t
s
i
n
i
n
v
a
s
i
v
e
a
d
e
n
o
c
a
r
c
i
n
o
m
a
N
o
t
r
e
p
o
r
t
e
d
M
M
T
V
-
C
r
e
p
r
o
m
o
t
e
r
-
d
r
i
v
e
n
;
f
o
c
a
l
l
y
i
n
v
a
s
i
v
e
c
a
r
c
i
n
o
m
a
a
t
1
0
w
e
e
k
s
M
i
c
e
d
i
e
f
r
o
m
l
y
m
p
h
o
m
a
s
a
t
1
4
w
k
s
2
0
0
4
[
8
9
]
P
S
A
C
r
e
/
P
t
e
n
l
o
x
p
/
l
o
x
p
C
o
n
d
i
t
i
o
n
a
l
S
i
n
g
l
e
E
x
o
n
5
F
V
B
/
n
/
1
2
9
O
l
a
I
n
v
a
s
i
v
e
a
d
e
n
o
c
a
r
c
i
n
o
m
a
N
o
t
r
e
p
o
r
t
e
d
P
S
A
-
C
r
e
p
r
o
m
o
t
e
r
-
d
r
i
v
e
n
;
a
l
l
m
i
c
e
d
e
v
e
l
o
p
a
d
e
n
o
c
a
r
c
i
n
o
m
a
a
t
1
0
–
1
4
m
o
n
t
h
s
w
i
t
h
r
a
r
e
m
e
t
a
s
t
a
s
e
s
2
0
0
5
[
8
6
]
P
S
A
C
r
e
/
P
t
e
n
l
o
x
p
/
l
o
x
p
C
o
n
d
i
t
i
o
n
a
l
S
i
n
g
l
e
E
x
o
n
s
4
a
n
d
5
C
5
7
B
L
/
6
H
o
m
o
z
y
g
o
u
s
d
e
l
e
t
i
o
n
r
e
s
u
l
t
s
i
n
i
n
v
a
s
i
v
e
a
d
e
n
o
c
a
r
c
i
n
o
m
a
a
n
d
m
e
t
a
s
t
a
t
i
c
s
p
r
e
a
d
t
o
l
y
m
p
h
n
o
d
e
s
Y
e
s
P
S
A
-
C
r
e
p
r
o
m
o
t
e
r
-
d
r
i
v
e
n
;
5
0
%
i
n
c
i
c
e
n
c
e
o
f
a
d
e
n
o
c
a
r
c
i
n
o
m
a
a
t
1
0
w
e
e
k
s
,
l
y
m
p
h
n
o
d
e
m
e
t
a
s
t
a
s
i
s
>
1
2
m
o
n
t
h
s
2
0
1
2
[
a
]
P
b
-
C
r
e
4
/
P
t
e
n
l
o
x
P
/
l
o
x
P
/
T
r
p
5
3
l
o
x
P
/
l
o
x
P
C
o
n
d
i
t
i
o
n
a
l
C
o
m
p
o
u
n
d
E
x
o
n
s
4
a
n
d
5
1
2
9
S
v
J
y
/
C
5
7
B
L
/
6
H
o
m
o
z
y
g
o
u
s
d
e
l
e
t
i
o
n
r
e
s
u
l
t
s
i
n
i
n
v
a
s
i
v
e
a
d
e
n
o
c
a
r
c
i
n
o
m
a
N
o
t
r
e
p
o
r
t
e
d
A
R
R
2
P
B
-
C
r
e
p
r
o
m
o
t
e
r
-
d
r
i
v
e
n
;
i
n
v
a
s
i
v
e
a
d
e
n
o
c
a
r
c
i
n
o
m
a
a
t
4
–
6
m
o
n
t
h
s
w
i
t
h
m
e
a
n
s
u
r
v
i
v
a
l
o
f
5
m
o
n
t
h
s
2
0
0
5
[
8
8
]
P
B
C
r
e
4
/
P
t
e
n
+
/
l
o
x
P
/
F
G
F
8
b
C
o
n
d
i
t
i
o
n
a
l
C
o
m
p
o
u
n
d
E
x
o
n
5
C
5
7
B
L
/
6
/
D
B
A
2
x
1
2
9
/
B
A
L
B
/
c
H
o
m
o
z
y
g
o
u
s
d
e
l
e
t
i
o
n
r
e
s
u
l
t
s
i
n
i
n
v
a
s
i
v
e
a
d
e
n
o
c
a
r
c
i
n
o
m
a
a
n
d
m
e
t
a
s
t
a
t
i
c
s
p
r
e
a
d
t
o
l
y
m
p
h
n
o
d
e
s
N
o
t
r
e
p
o
r
t
e
d
A
R
R
2
P
B
-
C
r
e
p
r
o
m
o
t
e
r
-
d
r
i
v
e
n
;
a
c
t
i
v
a
t
i
o
n
o
f
F
G
F
8
b
a
n
d
h
e
t
e
r
o
z
y
g
o
u
s
l
o
s
s
o
f
P
t
e
n
c
o
o
p
e
r
a
t
e
i
n
t
h
e
l
a
t
e
-
o
n
s
e
t
i
n
d
u
c
t
i
o
n
o
f
m
e
t
a
s
t
a
t
i
c
p
r
o
s
t
a
t
e
c
a
n
c
e
r
w
i
t
h
h
i
g
h
i
n
c
i
d
e
n
c
e
2
0
0
6
[
8
7
]
P
S
A
C
r
e
E
R
T
2
/
P
t
e
n
l
o
x
p
/
l
o
x
p
I
n
d
u
c
i
b
l
e
c
o
n
d
i
t
i
o
n
a
l
S
i
n
g
l
e
E
x
o
n
s
4
a
n
d
5
1
2
9
S
v
J
y
/
C
5
7
B
L
/
6
/
F
V
B
/
n
H
o
m
o
z
y
g
o
u
s
d
e
l
e
t
i
o
n
r
e
s
u
l
t
s
i
n
i
n
v
a
s
i
v
e
a
d
e
n
o
c
a
r
c
i
n
o
m
a
a
f
t
e
r
t
a
m
o
x
i
f
e
n
t
r
e
a
t
m
e
n
t
N
o
t
r
e
p
o
r
t
e
d
T
a
m
-
i
n
d
u
c
i
b
l
e
C
r
e
-
E
R
T
2
r
e
c
o
m
b
i
n
a
s
e
u
n
d
e
r
t
h
e
c
o
n
t
r
o
l
o
f
t
h
e
h
u
m
a
n
P
S
A
p
r
o
x
i
m
a
l
p
r
o
m
o
t
e
r
2
0
0
8
[
9
0
]
N
k
x
3
.
1
C
r
e
E
R
T
2
/
P
t
e
n
l
o
x
p
/
l
o
x
p
I
n
d
u
c
i
b
l
e
c
o
n
d
i
t
i
o
n
a
l
S
i
n
g
l
e
E
x
o
n
5
C
5
7
B
L
/
6
/
1
2
9
/
S
v
H
o
m
o
z
y
g
o
u
s
d
e
l
e
t
i
o
n
r
e
s
u
l
t
s
i
n
i
n
v
a
s
i
v
e
a
d
e
n
o
c
a
r
c
i
n
o
m
a
a
f
t
e
r
t
a
m
o
x
i
f
e
n
t
r
e
a
t
m
e
n
t
Y
e
s
T
a
m
-
i
n
d
u
c
i
b
l
e
C
r
e
-
E
R
T
2
r
e
c
o
m
b
i
n
a
s
e
u
n
d
e
r
t
h
e
c
o
n
t
r
o
l
o
f
t
h
e
N
k
x
3
.
1
p
r
o
m
o
t
e
r
2
0
0
9
[
9
1
]
a
D
e
V
e
l
a
s
c
o
e
t
a
l
.
[
9
5
]
.Advances in Urology 7
an intact immune system, thus incorporating all the impor-
tant components of innate and acquired immunity. Lastly, as
in humans, tumors in these mice show heterogeneity, a key
feature of cancer.
Despite all of the advantages over xenograft models,
concerns exist whether tumors arising from GEM are
homologous to human prostate cancers. Compared to the
human prostate which is divided into zones, the mouse
prostate develops as a lobular structure consisting of the
anterior, dorsal, lateral, and ventral lobes [97]. Some believe
that the dorsolateral lobes of the mouse prostate are the most
similar to the human peripheral zone, which is the region
where most cancers arise [96–98]. However, the Bar Harbor
pathology panel for genetically modiﬁed mouse models of
prostate cancer had the consensus opinion that there is no
direct relationship between the lobes of mouse prostates
and human prostate zones [97]. Nevertheless, GEM oﬀer a
unique tool for biomedical research in the understanding of
biochemical and disease pathways and the development of
newtherapeuticstrategiesthroughnewtargetandbiomarker
discovery and validation.
The evolution of newer generation transgenic mice based
on the conditional mutation, deletion, or insertion of single
or multiple targeted genes is becoming an attractive model
for researchers in academia and industry. As a result, mice
develop tumors which feature many similarities to human
prostatecancerincludingvariouspathologicalandmolecular
characteristics [84–86, 96]. Since tumors in these mice
arise from normal tissues, preclinical trials can be designed
to target speciﬁc points during tumor development that
take advantage of the windows of opportunity provided. A
developing paradigm for new treatments strategies involves
the use of combination-targeted therapies. Tumor growth
is not dependent on one particular signaling pathway,
rather, it is an orchestrated event that is driven by complex
feedback loops from crosstalk between multiple signaling
pathways. PTEN and bigenic knockout mice are excellent
models to investigate the preclinical therapeutic eﬀects from
combinatorial treatment strategies. Treatment strategies can
be designed as either horizontal or vertical to inhibit targets
involved in altered signaling pathways resulting from PTEN
inactivation.
PI3K/Akt/mTOR inhibitors are currently being evalu-
ated in various tumor types. mTORC1 inhibitors such as
rapamycin and rapalogs have demonstrated limited success
as single agent treatments [28, 99–101]. This lack of eﬃcacy
is attributed to the inability to maintain reduced levels of
phosphorylated 4E-BPs resulting from upregulation of Akt
through the loss of the S6K to IRS-1 negative feedback
regulation loop [100, 102, 103]. However, published reports
also suggest that crosstalk between RAS/RAF/MEK signal-
ing after mTOR inhibition results in resistance to mTOR
inhibitors. Humans with advanced prostate cancer treated
with RAD001 show schedule-dependent increases of MAPK
signaling activation [104]. Data from two independent stud-
ies conducted with PTEN knockout mice demonstrate that
dual inhibition of PI3K/Akt/mTOR and MAPK signaling
results in synergetic antitumor responses and is at least
feasible in a preclinical setting [104, 105].
Although Ras mutations in prostate cancer are infre-
quent, wild-type Ras is chronically activated in prostate
cancer as a result of autocrine and paracrine growth factor
stimulation [66, 106]. Upregulation of MAPK signaling in
prostate cancer is likely due to overexpression of growth
factor receptors. Several growth factor receptors including
the epidermal growth factor receptor (EGFR) and insulin-
like growth factor-1 receptor (IGF-1R) have been shown
to be overexpressed in prostate cancer. EGFR belongs to
the ErbB family of receptor tyrosine kinase proteins and
is highly expressed in primary tumors and metastases. In
prostate cancer, EGFR overexpression is associated with poor
prognosisandthetransitiontoCRPCstatus[107,108].Ithas
also been shown that Ras activation can play a causal role in
moving PCa cells towards decreased hormone dependence
and an increased malignant phenotype [109]. The role of
MAPK signaling, as a target for prostate cancer therapy,
becomes complicated as others report that MAPK signaling
may be inhibited in advanced prostate cancer due to the
deletion of the PTEN [110–112]. Akt activation, through
the deletion of PTEN, can result in the phosphorylation and
inactivation of Raf-1 thus decreasing downstream signaling
of MEK and ERK which then leads to the loss of cellular
diﬀerentiation [111, 113]. Evidence of crosstalk between
PI3K/Akt/mTOR and MAPK signaling pathways suggests
that compensatory survival signaling exists in this network
and could therefore be exploited therapeutically [114].
The transcription factor, signal transducer and activator
of transcription 3 (Stat3), has been implicated in the
growth and progression of several cancer types including
prostate [77, 115–118]. Stat3 has been shown to directly
and indirectly regulate the expression of genes required for
proliferation and apoptosis and is also known to negatively
regulatetheexpressionofp53,stimulatetumorangiogenesis,
and suppress antitumor immune responses [77, 119–121].
Stat3 has been shown to induce the metastatic behavior of
prostate cancer cells in vitro and in vivo [77]. Activation
of Stat3 occurs by the binding of various cytokines which
become constitutively activated by their respective ligands
by an autocrine and paracrine manner [120, 122]. Stat3
is also activated by growth factors as a downstream tar-
get of PI3K/Akt/mTOR and MAPK signaling through the
phosphorylation of Ser-727 [121, 123]. Activated IL-6 has
been shown to be elevated in the sera from patients with
metastaticprostatecancer.InadditiontoactivatingStat3,IL-
6 can also induce MAPK activation through various distinct
mechanisms [124–127]. Combined targeted inhibition of
PI3K/Akt/mTOR, RAS/RAF/MEK, and JAK/STAT signaling
may be a promising strategy for the treatment of prostate
cancer and PTEN knockout mice should play an important
role in the preclinical development and discovery of candi-
date agents.
7. PTEN Knockout Mice in
Biomarker Discovery
To eﬀectively treat human prostate cancer, one must be able
to identify speciﬁc targets that drive molecular and cellular
events to tumorigenesis. Cancer-related cellular processes8 Advances in Urology
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Figure 1: Modeling prostate cancer in the PTEN conditional knockout mouse model. (A) PSACre/PTENloxP/loxP can be used to screen for
tumor response against targeted therapies in chemoprevention, intervention, or regression models using noncastrated or castrated mice.
(B) Comprehensive genomic and proteomic analyses can be performed in PSACre/PTENloxP/+, PSACre/PTENloxP/loxP, or bigenic mutants to
identify candidate genes or proteins signatures aberrantly expressed between diﬀerent pathologic, genomic, or temporal disease conditions.
(C) Cooperation between genetic and nongenetic factors can be assessed in tumor development in both homozygous and heterozygous
PTEN-conditional mutant mice.
are being studied to identify possible targets for new
drug development and biomarker discovery. However, drug
target and biomarker discovery using human samples is
diﬃcult and hampered by the amount of genetic variation
among individuals as well as external inﬂuences (lifestyle
and environmental factors) that contribute to the patho-
genesis of the prostate cancer [128–130]. Furthermore,
this requires the acquisition of large numbers of samples
which is time consuming and may be diﬃcult in many
instances. Interspecies conservation of genomic aberrations
across conserved regions of tumorigenesis provides an
alternative approach to identify genes responsible for tumor
developments and progression [15, 131]. Transgenic mice
have lower biological variances and can be studied under
controlledsituationsthatbetterenablethedetectionoftarget
molecules. Because of this, transgenic mouse models of
prostate cancer, in particular PTEN-mutant mice, provide a
unique opportunity for the discovery of novel targets.
8. Concluding Remarks
Further advances in the treatment strategies for prostate can-
cer are dependent on the development, use, and incorpora-
tion of clinically relevant faithful animal models of human
prostate cancer (Figure 1). Recent work on PTEN mouse
models has helped characterize human prostate carcinogen-
esis. Although these models share amazing similarity to the
pathobiology of human prostate cancer, diﬀerences between
human and mouse kinetics, physiology, and metabolism
must be considered. Despite these limitations, PTEN knock-
out mice will continue to be used to further characterize
prostate carcinogenesis. The use of these models in preclin-
ical drug, target, and biomarker discovery and development
will increase and will most likely become a standard in drug
discovery pipeline.
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